Assertion criteria |
Genetic Evidence (0-12 points) |
Experimental Evidence
(0-6 points) |
Total Points
(0-18)
|
Replication Over Time (Y/N) |
Description |
Case-level, family segregation, or case-control data that support the gene-disease association
|
Gene-level experimental evidence that support the gene-disease association |
Sum of Genetic & Experimental
Evidence
|
> 2 pubs w/ convincing evidence over time (>3 yrs) |
Assigned Points |
=$inputThisData["summary"]["GeneticEvidenceTotal"]?>
0
|
=$inputThisData["summary"]["ExperimentalEvidenceTotal"]?>
0
|
=$inputThisData["summary"]["EvidencePointsTotal"]?>
0
|
NO
|
CALCULATED CLASSIFICATION |
LIMITED |
1-6 |
MODERATE |
7-11 |
STRONG |
12-18 |
DEFINITIVE |
12-18 AND replication over time |
Valid contradictory evidence (Y/N)*
|
|
CALCULATED CLASSIFICATION (DATE) |
No Classification
07/24/2018
|
MODIFY CALCULATED CLASSIFICATION
|
YES
|
MODIFIED CLASSIFICATION (DATE)
|
No Reported Evidence
07/24/2018
|
REASON(S) FOR CHANGE
|
NE
|
EXPERT CURATION (DATE) |
No Reported Evidence
07/24/2018
|
EVIDENCE SUMMARY |
No published evidence to date has implicated an association between HRAS variants and cardiofaciocutaneous syndrome (CFC).
|